Table 1.

Recommend indications of amyloid PET

Amyloid PET imaging is appropriate for

(1) Patients with mild cognitive impairment, in whom clinical uncertainty exists

(2) Patients with a dementia syndrome suggestive of AD, but with an atypical presentation or suspected mixed cause

(3) Patients with early-onset progressive cognitive decline (usually defined as 65 years or less in age)

(4) Patients meeting clinical core criteria for a probable diagnosis of AD when the information on amyloid status is required for managementa

(5) Patients with a diagnosis of SCD meeting the core clinical criteria for SCD-plusa

Amyloid PET imaging is inappropriate for

(6) Determining dementia severity

(7) The study solely based on a positive family history of dementia or presence of APOE ε4

(8) Patients with a cognitive complaint that is unconfirmed by clinical examination

(9) Instead of genotyping for suspected autosomal mutation carriers

(10) Asymptomatic individuals

(11) Nonmedical usage (e.g., legal, insurance coverage, or employment screening)

PET Positron emission tomography, AD Alzheimer’s disease, SCD Subjective cognitive decline, APOE Apolipoprotein E

^aUpdated indications on appropriate use criteria (AUC) for Amyloid PET imaging posited by the Alzheimer's Association and the Society of Nuclear Medicine and Molecular Imaging launched in 2013 (Donohue et al. 2017; Johnson et al. 2013a)